The success of KRASG12C allele-specific inhibitors has pushed research on targeting KRAS to a new level, which may lead to the development of more promising KRAS-targeted approaches and provide the possibility for conquering KRAS mutations in CRC. This evidence concerns the gene KRAS and colorectal carcinoma.